|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Addition of statins to the standard treatment in patients with cirrhosis:Safety and efficacy显示文摘This review summarizes the safety and efficacy of statins in patients with cirrhosis.Due to concerns about the safety of statins in patients with impaired liver function,they have recently been investigated as a potential treatment option in cirrhosis.The most clinically significant adverse event is statin-related myopathy,and this may be related to the high serum statin concentrations in the setting of severely impaired liver function.Rhabdomyolysis is the most serious and potentially life-threatening manifestation.It has recently been demonstrated that the recommended dose of simvastatin in patients with decompensated cirrhosis would be 20 mg/d because higher values,such as 40 mg/d,are associated with many adverse events,especially muscle injury.Likewise,simvastatin should not be administered to patients with Model for End-stage Liver Disease score>12 and/or Child-Pugh class C because of the high risk of severe muscle injury.Due to the pleiotropic effects,the focus on statins has shifted from being considered harmful to something useful.Through these effects,statins could prevent liver-related morbidity and mortality in cirrhotic patients.Observational studies in large populations of patients with cirrhosis have shown that treatment with statins to decrease high cholesterol levels was associated with a reduced risk of hepatic decompensation,hepatocellular carcinoma development and death.The few randomized controlled trials in patients with cirrhosis and portal hypertension showed that statins lower portal pressure,quite likely through a reduction in hepatic resistance.Another large randomized controlled trial in patients with variceal bleeding showed that simvastatin in addition to standard of care did not prevent rebleeding but improved survival rate.Despite these encouraging outcomes,the quality of the evidence regarding the use of statins is low or very low due to the observational characteristics of most of the studies involved.Therefore,it is advisable to perform further randomized controlled trials on a large series of patients with hard clinical endpoints,using different statin types and varying doses.The objectives would be to prevent liver-related morbidity and mortality rather than treating cirrhosis complications to take additional information that makes it possible to add statins to the standard of care of these patients. | Alberto E Muñoz Florencia D Pollarsky Mónica Marino Mariano Cartier Horacio Vázquez Pablo Salgado Gustavo Romero | 2021 | World Journal of Gastroenterology2021，27，28： | 4 |
| 2 | Fatty liver disease,an emerging etiology of hepatocellular carcinoma in Argentina显示文摘AIM To investigate any changing trends in the etiologies of hepatocellular carcinoma(HCC) in Argentina during the last years. METHODS A longitudinal cohort study was conducted by 14 regional hospitals starting in 2009 through 2016. All adult patients with newly diagnosed HCC either with pathology or imaging criteria were included. Patients were classified as presenting non-alcoholic fatty liver disease(NAFLD) either by histology or clinically, provided that all other etiologies of liver disease were ruled out, fatty liver was present on abdominal ultrasound and alcohol consumption was excluded. Complete follow-up was assessed in all included subjects since the date of HCC diagnosis until death or last medical visit.RESULTS A total of 708 consecutive adults with HCC were included. Six out of 14 hospitals were liver transplant centers(n = 484). The prevalence of diabetes mellitus was 27.7%. Overall, HCV was the main cause of liver disease related with HCC(37%) including cirrhotic and non-cirrhotic patients, followed by alcoholic liver disease 20.8%, NAFLD 11.4%, cryptogenic 9.6%, HBV 5.4% infection, cholestatic disease and autoimmune hepatitis 2.2%, and other causes 9.9%. A 6-fold increase in the percentage corresponding to NAFLDHCC was detected when the starting year, i.e., 2009 was compared to the last one, i.e., 2015(4.3% vs 25.6%; P < 0.0001). Accordingly, a higher prevalence of diabetes mellitus was present in NAFLD-HCC group 61.7% when compared to other than NAFLD-HCC 23.3%(P < 0.0001). Lower median AFP values at HCC diagnosis were observed between NAFLD-HCC and non-NAFLD groups(6.6 ng/m L vs 26 ng/m L; P = 0.02). Neither NAFLD nor other HCC etiologies were associated with higher mortality.CONCLUSION The growing incidence of NAFLD-HCC documented in the United States and Europe is also observed in Argentina, a confirmation with important Public Health implications. | Federico Pinero Josefina Pages Sebastián Marciano Nora Fernández Jorge Silva Margarita Anders Alina Zerega Ezequiel Ridruejo Beatriz Ameigeiras Claudia D’Amico Luis Gaite Carla Bermúdez Manuel Cobos Carlos Rosales Gustavo Romero Lucas McCormack Virginia Reggiardo Luis Colombato Adrián Gadano Marcelo Silva | 2018 | World Journal of Hepatology2018，10，1： | 4 |
| 3 | Intermediate-advanced hepatocellular carcinoma in Argentina:Treatment and survival analysis显示文摘BACKGROUND Hepatocellular carcinoma(HCC) represents the sixteenth most frequent cancer in Argentina. The rise of new therapeutic modalities in intermediate-advanced HCC opens up a new paradigm for the treatment of HCC.AIM To describe real-life treatments performed in patients with intermediateadvanced HCC before the approval of new systemic options.METHODS This longitudinal observational cohort study was conducted between 2009 and2016 in 14 different regional hospitals from Argentina. Included subjects had intermediate-advanced Barcelona Clinic Liver Cancer(BCLC) HCC stages(BCLC B to D). Primary end point analyzed was survival, which was assessed for each BCLC stage from the date of treatment until last patient follow-up or death.Kaplan Meier survival curves and Cox regression analysis were performed, with hazard ratios(HR) calculations and 95% confidence intervals(95%CI).RESULTS From 327 HCC patients, 41% were BCLC stage B, 20% stage C and 39% stage D.Corresponding median survival were 15 mo(IQR 5-26 mo), 5 mo(IQR 2-13 mo)and 3 mo(IQR 1-13 mo)(P < 0.0001), respectively. Among BCLC-B patients(n =135), 57% received TACE with a median number of 2 sessions(IQR 1-3 sessions).Survival was significantly better in BCLC-B patients treated with TACE HR =0.29(CI: 0.21-0.40) than those without TACE. After tumor reassessment by RECIST 1.1 criteria following the first TACE, patients with complete response achieved longer survival (HR = 0.15(CI: 0.04-0.56, P = 0.005))Eighty-two patients were treated with sorafenib, mostly BCLC-B and C(87.8%). However,12.2% were BCLC-D. Median survival with sorafenib was 4.5 mo(IQR 2.3-11.7 mo);which was lower among BCLC-D patients 3.2 mo(IQR 2.0-14.1 mo). A total of 36 BCLC-B patients presented tumor progression after TACE. In these patients,treatment with sorafenib presented better survival when compared to those patients who received sorafenib without prior TACE [HR = 0.26(CI: 0.09-0.71);P= 0.013].CONCLUSION In this real setting, our results were lower than expected. This highlights unmet needs in Argentina, prior to the introduction of new treatments for HCC. | Federico Pinero Sebastián Marciano Nora Fernández Jorge Silva Margarita Anders Alina Zerega Ezequiel Ridruejo Gustavo Romero Beatriz Ameigeiras Claudia D’Amico Luis Gaite Carla Bermúdez Virginia Reggiardo Luis Colombato Adrián Gadano Marcelo Silva | 2019 | World Journal of Gastroenterology2019，25，27： | 3 |
| 4 | Omega-3 fatty acid supplementation reduces one-year risk of atrial fibrillation in patients hospitalized with myocardial infarction显示文摘 | Alejandro Macchia Simona Monte Fabio Pellegrini Marilena Romero Daniel Ferrante Hernán Doval Antonio D'Ettorre Aldo Pietro Maggioni Gianni Tognoni | 2008 | European Journal of Clinical Pharmacology2008，，6： | 2 |
| 5 | Clinical characteristics and type of antithrombotic treatment in a Spanish cohort of elderly patients with atrial fibrillation according to dependency, frailty and cognitive impairment显示文摘根据相关性,脆弱和认知缺陷与 atrial 纤维性颤动(AF ) 考虑老病人的临床的侧面和管理的 BackgroundAvailable 数据是少见的。学习的目的是根据相关性分析 biodemographic 数据,临床的侧面和 antithrombotic 治疗,吗在patients.MethodsCross部分的老 AF 和学习在 75 年与 3 个月在 Spain.ResultsA 在内部药部门出席了的口头的抗凝剂对待的连续 AF 病人执行了的多中心的脆弱和认知缺陷 837 总计病人( 83.0 ???????????????????吗???????????????????￡?? | Jose Maria Mostaza Manuel Jesús Romero Jiménez Fernando José Ruiz Laiglesia José Antonio Díaz Peromingo Manuel Beltrán Robles Ernesto Guevara Sierra Ana Santander Bilbao Carmen Suárez | 2018 | Journal of Geriatric Cardiology2018，15，4： | 2 |
| 6 | Distinct subsets of microRNAs are expressed differentially in the human placentas of patients with preeclampsia 显示文摘 | Pineles BL Romero R Montenegro D | 2007 | Am J Obstet Gynecol2007，196，3： | 1 |
| 7 | Modelling the kinetics of growth of Acetobacter aceti in discontinuous culture: influence of the temperature of operation显示文摘 | DE ORY I ROMERO LE CANTERO D | 1998 | Appl Mierobiol Biotechnol1998，49，2： | 1 |
| 8 | Robust two-dimensional weighted and unweighted phase unwrapping that uses fast transforms and iterative methods显示文摘 | Ghiglia D C Romero L A | 1994 | J Opt Soc Am1994，11，1： | 1 |
| 9 | Endoglin struc ture and function: Determinants of endoglin phosphoryla tion by transforming growth factor beta receptors显示文摘 | Koleva RI Conley BA Romero D | 2006 | Biol Chem2006，281，25： | 1 |
| 10 | Evidence for a stereotypic difference in post-transcriptional regulation of placental gene expression in preeclampsia and SGA:An explanation for the two different phenotypes? 显示文摘 | Pineles BL Romero R Montenegro D | 2006 | Am J Obstet Gynecol2006，195，6： | 1 |
| 11 | Temperature conversion (mesophilic to thermophilic) of municipal sludge digestion 显示文摘 | De la Rubia M A Romero L I Sales D | 2005 | Aiche Journal2005，51，9： | 1 |
| 12 | Comparison of different gait with rotation of the feet for planar biped显示文摘 | Tlalolini Romero D Chevallereau C Aoustin Y | 2009 | Robotics and Autonomous Sys- tems2009，57，4： | 1 |
| 13 | Partial protection against in- fectious bursal disease virus through DNA-mediated vaccination with the VP2 capsid protein and chicken IL-2 genes显示文摘 | Hulse D J Romero C H | 2004 | Vaccine2004，22，： | 1 |
| 14 | Chemical characterization of Opuntia dillenii and Opuntia ficus indica fruits显示文摘 | E.M. Díaz Medina E.M. Rodríguez Rodríguez C. Díaz Romero | 2006 | Food Chemistry2006，，1： | 1 |
| 15 | The pow- dery mildew fungus Podosphaera fusca (synonym Podosphaera xan- thii) ,a constant threat to eucurbits显示文摘 | Perez-Garcia A Romero D Fernandez-Ortuno D | 2009 | Molecular Plant Pathology2009，10，2： | 1 |
| 16 | Grid cell distortion and modflow' s integrated finit-difference numerical solution 显示文摘 | Romero D M Silver S E | 2006 | Groundwater2006，44，6： | 1 |
| 17 | Tissue factor and its natural inhibitor in pre-eclampsia and SGA 显示文摘 | Erez O Romero R Hoppensteadt D | 2008 | J Matern Fetal Neonatal Med2008，21，： | 1 |
| 18 | Delayed postoperative latent pain sensitization revealed by the systemic administration of opioid antagonists in mice显示文摘 | CAMPILLO A CABAERO D ROMERO A | 2011 | Eur J Pharmacol2011，2，13： | 1 |
| 19 | Plant protection and growth stimulation by microorganisms: biotechnological applica- tions of Bacilli in agriculture显示文摘 | P6rez-Garcia A Romero D de Vicente A | 2011 | Current Opinion in Biotech- nology2011，22，2： | 1 |
| 20 | pH- Dependent Gating in the Streptomyces lividans K^+ Channel显示文摘 | CUELLO L ROMERO J CORTES D | 1998 | Biochemistry1998，37，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员